[Chronic nephritic syndrome].
Shibasaki
Toshiaki
T
Department of Pharmacotherapeutics, Kyoritsu College of Pharmacy.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D002908:Chronic Disease; D003937:Diagnosis, Differential; D018753:Diet, Protein-Restricted; D004039:Diet, Sodium-Restricted; D005914:Globins / Q000008:administration & dosage; D005921:Glomerulonephritis / Q000145:classification / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011239:Prednisolone / Q000008:administration & dosage; D012254:Ribavirin / Q000627:therapeutic use; D013577:Syndrome
D000806:Angiotensin-Converting Enzyme Inhibitors; D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D012254:Ribavirin; D005914:Globins; D011239:Prednisolone